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Previous linkage studies in schizophrenia have been discouraging due to inconsistent ﬁndings and weak signals.
Genetic heterogeneity has been cited as one of the primary culprits for such inconsistencies. We have performed a
10-cM autosomal genomewide linkage scan for schizophrenia susceptibility regions, using 29 multiplex families of
Ashkenazi Jewish descent. Although there is no evidence that the rate of schizophrenia among the Ashkenazim
differs from that in other populations, we have focused on this population in hopes of reducing genetic heterogeneity
among families and increasing the detectable effects of any particular locus. We pursued both allele-sharing and
parametric linkage analyses as implemented in Genehunter, version 2.0. Our strongest signal was achieved at
chromosome 10q22.3 (D10S1686), with a nonparametric linkage score (NPL) of 3.35 (genomewide empirical
) and a dominant heterogeneity LOD score (HLOD) of 3.14. Six other regions gave NPL scores 12.00Pp .035
(on chromosomes 1p32.2, 4q34.3, 6p21.31, 7p15.2, 15q11.2, and 21q21.2). Upon follow-up with an additional
23 markers in the chromosome 10q region, our peak NPL score increased to 4.27 (D10S1774; empirical Pp
), with a 95% conﬁdence interval of 12.2 Mb for the location of the trait locus (D10S1677 to D10S1753)..00002
We ﬁnd these results encouraging for the study of schizophrenia among Ashkenazi families and suggest further
linkage and association studies in this chromosome 10q region.
Introduction
Schizophrenia and schizoaffective disorder (MIM
181500), which are hereafter referred to as “SZ,” con-
stitute a complex psychiatric disorder that currently af-
fects ∼1% of the world populations (Eaton 1985). Al-
though the causes are yet unknown, many lines of
evidence, including twin, adoption, and family studies,
support a strong genetic component (McGue and Got-
tesman 1991; Tsuang et al. 1991; Cardno and Gottes-
man 2000). Such observations have motivated an enor-
mous amount of work toward the discovery of genes
involved in SZ, including many genomewide linkage
scans and a multitude of candidate gene investigations
(Pulver et al. 1994, 1995; Moises et al. 1995; Straub et
al. 1995, 1997, 1998, 2002; Wang et al. 1995; Kendler
et al. 1996; Schwab et al. 1997, 1998, 2000, 2003;
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Blouin et al. 1998; Faraone et al. 1998; Brzustowicz et
al. 1999, 2000; Levinson et al. 2000; Egan et al. 2001;
Gurling et al. 2001; DeLisi et al. 2002; Shifman et al.
2002; Stefansson et al. 2002, 2003).
Although recent data suggest a role for neuregulin 1
(NRG1 [MIM 142445], mapped to chromosome 8p12)
in SZ susceptibility in Icelandic and Scottish samples
(Stefansson et al. 2002, 2003), the ﬁeld is generally
plagued with inconsistent results across studies. Every
human chromosome, in one or another study, has
shown some evidence of harboring an SZ gene, but none
is consistent across all studies. For example, two meta-
analyses of genomewide SZ scans have recently been
published, with differing results. Badner and Gershon
(2002) conducted meta-analyses based on published SZ
scans, using the multiple-scan-probability (MSP) tech-
nique to analyze 18 genomewide scans (681 pedigrees),
and showed that the strongest evidence for susceptibility
loci exists on chromosomes 8p, 13q, and 22q, the three
regions previously implicated in our autosomal scan of
54 pedigrees of European descent (Blouin et al. 1998).
Lewis et al. (2003) applied a rank-based genome scan
meta-analysis to genotype data from 20 genomewide
SZ scans and found that, when this method was used,
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Table 1
Structure of 29 Ashkenazi Jewish Families Used in Scan
Relationship Type
No. of
Affected
Sibsa
No. of
Foundersb
Frequency
of Families
by Type
Siblings (No./Family):
2 2 2 11
2 2 1 4
2 2 0 1
3 2 2 2
3 2 1 3
3 2 0 2
4 3 1 1
4 2 1 1
Avuncular NA 2 1
Grandparent-grandchild NA 2 1
Cousins NA 4 2
Total 29
a NA p not applicable.
b No. of genotyped parents for sibships; no. of genotyped
founders for other relationship types.
the strongest evidence of linkage was on chromosome
2q.
The reasons for such inconsistencies likely stem from
the complex nature of SZ etiology. Several genes, acting
additively or in concert, may be responsible for SZ in
some families, whereas other genetic combinations may
explain the disorder in other subgroups. Thus, linkage
studies to date have unwittingly combined families of
different genetic etiologies into one test group. Although
this approach has proved fruitful for many highly pen-
etrant Mendelian disorders, the heterogeneity problem
is a much greater concern when looking for several
genes of modest-to-small effects.
One approach to reduce heterogeneity is to pursue
families from a relatively genetically isolated population
that has emerged from a small number of founders
(McKusick 1973; Peltonen et al. 2000; Shifman et al.
2002). This increases the likelihood that the subjects
genotyped will have similar underlying genetic predis-
positions, increasing the ability to detect the effects of
a particular gene. This approach has been taken pre-
viously for genetic studies of SZ, including focus on
Finland (Hovatta et al. 1999; Ekelund et al. 2000; Pau-
nio et al. 2001; Gasperoni et al. 2003), Iceland (Moises
et al. 1995; Stefansson et al. 2002; Stefansson et al.
2003), the Central Valley of Costa Rica (DeLisi et al.
2002), the Azores (Pato et al. 1997), and Palau (Micro-
nesia) (Devlin et al. 2002).
We have collected a set of Ashkenazi Jewish families
with at least two individuals affected by SZ. The current
Ashkenazi Jewish population, living mostly in central
and eastern Europe and the United States, descended
from a small founder population ∼500 years ago (Ostrer
2001). The close genetic relationships among Ashke-
nazim have been documented through traces of several
Mendelian genetic disorders, as well as through Y chro-
mosome and mitochondrial similarities (Tikochinski et
al. 1991; Santachiara Benerecetti et al. 1993; Hammer
et al. 2000; Nebel et al. 2000, 2001). Because of the
reduced genetic variation, genetic studies among the
Ashkenazim have been productive in the identiﬁcation
of susceptibility genes for several disorders. Founder
mutations have been shown to be important as causes
of colorectal cancer (Foulkes et al. 2002), breast cancer
(Struewing et al. 1997), and prostate cancer (Rennert
et al. 2002) in the Ashkenazim. Even though the rate
of SZ does not appear to differ from the rates in other
populations, focus on this isolate can reduce hetero-
geneity in linkage analyses and increase the utility of
association analyses.
Subjects and Methods
Ascertainment of Study Subjects
SZ families of Ashkenazi descent were recruited na-
tionally with advertisements in newspapers and Jewish
newsletters, talks to community organizations, and the
Epidemiology-Genetics Program in PsychiatryWeb site).
Families were eligible for inclusion in these analyses if
the proband met criteria for a diagnosis of schizophre-
nia, according to the Diagnostic and Statistical Manual
of Mental Disorders, 4th edition (DSM-IV) (American
Psychiatric Association 1994), and if a ﬁrst- or second-
degree relative met DSM-IV criteria for schizophrenia or
schizoaffective disorder.We recruited 29multiply affected
families of Ashkenazi descent. Probands in these fam-
ilies were recruited from California (34%), the north-
eastern United States (New York, New Jersey, Penn-
sylvania, Rhode Island, and Maryland) (31%), the
midwestern United States and Canada (Wisconsin, Ohio,
Illinois, Minnesota, and Ontario) (21%), and the south-
ern United States (Florida and Mississippi) (10%). Our
ascertainment strategy for the multiply affected pedigrees
was to directly examine all affected individuals, the par-
ents of those individuals, and any other family members
connecting affected pairs. When parents of affected in-
dividuals were unavailable, we sought unaffected siblings
for DNA samples.
Diagnostic Instruments and Procedures
Affected individuals and their parents were examined
in person by a clinical psychologist (hereafter referred
to as the “clinical examiner”) with the administration
of two interviews. In addition, a blood sample was col-
lected. Most of the subjects were seen in their homes.
The two interview schedules were as follows: (1) the
Diagnostic Interview for Genetic Studies (DIGS, version
2.0; revised for DSM-IV), a semistructured interview
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that elicits information about lifetime history of psy-
chiatric symptoms and behaviors; and (2) the Structured
Interview for DSM-IV Personality Disorders (SID-P)
(Stangl et al. 1985). The SID-P schedule was adminis-
tered to non-SZ subjects and includes items relevant to
the assessment of the following subset of personality
disorders: antisocial, borderline, histrionic, compulsive,
schizoid, schizotypal, and paranoid. As part of the in-
terview process, a psychiatric treatment history was pre-
pared, and the subjects were asked to sign release forms
allowing us to receive copies of their psychiatric treat-
ment records. Interviews were tape-recorded for quality
control purposes and for review by members of a con-
sensus diagnosis committee, who assigned ﬁnal diag-
noses for each subject (see paragraph below). In addition
to interviewing the subject, the clinical examiner also
interviewed an informant about the subject. The clinical
examiner completed a written diagnostic formulation for
each affected individual, describing prominent features
and course of illness.
Final diagnoses were assigned through a consensus
procedure. Available information about each subject
(i.e., tape recording of the interview, interview booklets,
summary of information obtained from informant, clin-
ical examiner’s diagnostic formulation, and psychiatric
treatment records) was reviewed independently by two
members of a consensus diagnosis committee (psychia-
trists) who each completed a DSM-IV diagnostic check-
list. The checklist contained each necessary criterion for
26 Axis I DSM-IV disorders. Disorders were rated as
absent, possibly present, probably present, deﬁnitely
present, or unknown. Ages at onset of disorders that
were rated as present (for any level of certainty) were
also recorded. Ratings assigned independently by the
two members of the committee were compared. If dis-
agreement existed with respect to (1) the ratings of any
of the 26 diagnoses (including certainty levels assigned),
(2) age at onset (14-year discrepancy) for any of the
disorders that were rated as positive, or (3) course of
illness ratings for individuals with psychotic symp-
toms, then the two members of the committee met to
resolve the discrepancies. Fifty-nine subjects with cer-
tainty ratings of probably or deﬁnitely present for DSM-
IV schizophrenia or schizoaffective disorder were con-
sidered to be affected, thereby limiting our analyses to
a narrow and conservative deﬁnition of the affected phe-
notype for linkage analyses. Of the 59 affected subjects,
10 were given a consensus diagnosis of DSM-IV schi-
zoaffective disorder.
Demographic and Clinical Characteristics
The family structures in our data set are provided in
table 1. The families are generally small, with 26 of the
families consisting of affected sibling pairs and 3 families
consisting of other affected relative pairs. Affected in-
dividuals included those with schizophrenia (83%) or
schizoaffective disorder (17%); 66% of these affected
individuals were male. The average age at onset for all
affected individuals was 20.1 years (range 12–35 years)
and was similar for schizophrenia and schizoaffective
disorder cases. Individuals who were given a diagnosis
of another psychotic disorder or schizophrenia spectrum
disorder were classiﬁed as “phenotype unknown” in all
analyses. Nine subjects in the 29 pedigrees were assigned
to the unknown category (ﬁve with a psychotic affective
illness and four with an schizophrenia spectrum person-
ality disorder).
To reduce the possibility of non-Ashkenazi grandpar-
ents or founders in our sample, ancestry questionnaires
were completed for each proband to establish country
or region of origin of their parents and four grandpar-
ents. Eastern Europe (Russia, Poland, Latvia, Lithuania,
and Ukraine) and central Europe (Austria, Germany,
Hungary, and Romania) account for 198% of the
known grandparent countries of origin. Families were
excluded if any grandparent of an affected subject was
known to be of non-Ashkenazi descent.
Genotyping
All genotyping for this scan was performed at the
Australian Genome Research Center (AGRF). The au-
tosomal scan included 382 markers (ABI Prism Linkage
Mapping Set, version 2 [MD-10, LMSV2]), with an
average spacing of 8.85 cM, covering 3,381 cM, and
an average heterozygosity of 0.785. The largest gaps
were 24.1 cM on chromosome 8q12.1 and 23.8 cM on
6p21.31. Map order and distances were determined
from the Ge´ne´thon map. Markers were genotyped in 28
multiplexed panels. All PCRs were performed under
standard conditions in a total volume of 6 ml, using a
PTC-225 DNA Engine Tetrad (MJ Research). Primers
were labeled with ﬂuorescent dyes (FAM, HEX, and
NED [Applied Biosystems LMSV2]). PCR productswere
then pooled into multiplex panels of 10–20 markers and
electrophoresed for 2.8 h (0.2 mm denaturing polyacryl-
amide gels, 4.5%) on a 377 DNA Sequencer (Applied
Biosystems). Genescan software (Applied Biosystems)
assigns tracking for each sample lane. Files are then
imported into Genotyper (Applied Biosystems) soft-
ware that interprets the electropherogram and assigns
genotypes.
Follow-up markers for chromosome 10 were chosen
from the UCSC genome browser (Kent et al. 2002) (June
2002 assembly) to cover an average spacing of 1 Mb.
Priority was given to markers with the highest hetero-
zygosity. Map order and distance were based on the
UCSC map, except for two cases in which the DeCode
Icelandic map (Kong et al. 2002) was used.
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Table 2
Maximum Linkage Signal for Each Chromosome at Initial Genome Scan
CHROMOSOME
MODEL-FREE DOMINANTa RECESSIVEb
NPL Peak Marker cM Pc
Maximum
HLOD a (%)d cM
Maximum
HLOD a (%)d cM
1 2.45 D1S2797 68.0 .007 1.23 100 32.9 .90 35 167.3
2 1.40 D22S2259, D22S2368 59.1, 81.7 .081 .25 36 59.1 .27 23 85.0
3 1.62 D3S1263 27.1 .055 .78 60 31.9 1.22 40 117.4
4 2.30 D4S1535 197.7 .011 1.05 75 197.7 1.07 47 192.7
5 1.49 D5S407 66.3 .068 .31 55 40.3 .39 26 68.3
6 2.37 D6S1610 43.6 .009 1.17 78 53.1 2.09 71 57.9
7 2.09 D7S510 56.8 .019 .80 61 56.8 .98 41 53.7
8 1.12 D8S514 123.9 .13 .42 44 123.9 .63 30 123.9
9 1.68 D9S1682 126.4 .048 .80 68 13.7 .63 32 123.0
10 3.35 D10S1686 106.3 .00042 3.14 100 108.6 1.89 64 110.9
11 1.49 D11S905 51.9 .068 1.04 65 54.3 1.00 36 58.0
12 1.89 D12S79 131.3 .03 1.01 77 131.3 .90 34 118.5
13 1.36 D13S263 30.1 .088 .28 36 57.5 .51 26 30.1
14 .07 D14S65 108.2 .53 .03 13 33.2 .01 4 125.2
15 2.15 D15S128 0 .017 .45 50 0 .84 36 0
16 1.20 D6S3068 41.6 .12 .16 28 41.6 .84 33 41.6
17 .62 D17S938 15.0 .27 .38 45 15.0 .13 14 47.4
18 .91 D18S61 109.8 .181 .20 28 109.8 .08 11 109.8
19 .17 D19S220 49.7 .43 .06 16 49.7 .07 10 46.5
20 .19 D20S117 0 .43 .14 26 0 .15 16 24.8
21 2.04 D21S1914 14.0 .021 1.72 89 14.0 1.19 44 31.2
22 .55 D22S274 49.7 .292 .35 44 49.7 .07 11 49.7
a Dominant parametric HLOD scores calculated in Genehunter, version 2.0, assuming disease allele frequency of .005 and penetrances of
.65, .65, and .0096 for homozygotes, heterozygotes, and noncarriers, respectively.
b Recessive parametric HLOD scores assumed disease allele frequency of .11 and penetrances of .65, .0096, and .0096.
c Calculated using Genehunter.
d a p estimated proportion of linked families at this location.
Statistical Analyses
Mendelian inconsistencies and potential relationship
errors were evaluated and corrected prior to data anal-
ysis using the Pedmanager (v. 0.9) interface at AGRF
(Ewen et al. 2000). The AGRF software was also used
for binning of alleles, and Genehunter, version 2.0, was
used to identify double (ﬂanking) crossovers in haplo-
types. Markers were removed from subsequent analyses
for the entire family when Mendelian inconsistencies
were apparent, and markers were removed for individ-
uals when apparent double crossovers were identiﬁed in
Genehunter haplotypes. Parametric andmodel-free allele
sharing linkage analyses were performed using the soft-
ware Genehunter (Kruglyak et al. 1996). Parametric
LOD scores and heterogeneity LOD (HLOD) scores
were calculated for both dominant and recessivemodels.
Parameters for these models are noted in table 2. Model-
free allele sharing was assessed via the NPLall statistic,
based on estimated allele sharing for all affected relative
pairs in the data set. Marker allele frequencies among
the Ashkenazi were estimated on the basis of founders
from 60 Ashkenazi pedigrees collected for our psychi-
atric genetics studies (101 parents from families with
DSM-IV bipolar I disorder and SZ). This allowed amore
precise estimate of frequencies than relying on founders
in the 29 families with SZ. However, parents were avail-
able for most of our families (see table 1), so the impact
of these allele frequency estimates should not be large.
The NPLall method does not directly estimate the loca-
tion of a susceptibility locus, and one often assumes the
best location estimate to be where the NPLall is the high-
est. However, this is not ideal, and locations estimated
in this way can vary greatly (Roberts et al. 1999). For
this reason, we employed the method of Liang et al.
(2001) to directly estimate location by employing gen-
eralized estimating equations. This method is imple-
mented in the software Geneﬁnder and provides esti-
mates of map location (and the 95% CI) for the disease
locus (t).
Empirical P values were calculated for the NPLall
scores via simulation. The program Merlin (Abecasis et
al. 2002) was used to generate 50,000 replicates of fam-
ilies identical to those in our sample. Markers with sim-
ilar allele sizes and frequencies were also generatedunder
the assumption of no linkage. Linkage analyses were
then performed on these unlinked replicates (according
to the procedure of Li and Haghighi [1999]), and ge-
nomewide empirical P values were estimated by extrap-
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olating results for chromosome 1 to the whole-genome
level, assuming chromosome 1 represents 0.1 of the ge-
nome. For ﬁne mapping, chromosomewide empirical P
values were calculated as the proportion of replicates
showing an equal or more extreme NPL at any point
on the chromosome. Although recessive and dominant
model parametric analyses were also performed for each
chromosome, our inferences were based on NPL results,
and we therefore focused on this statistic when esti-
mating P values. Furthermore, these additional tests are
correlated (on average) with the NPL results and are not
likely to increase the overall type I error greatly.
Results
Initial Autosomal Scan Linkage Analyses
NPL plots for model-free analyses, as well as HLOD
plots for dominant and recessive parametric models, are
shown in ﬁgure 1. No initial linkage signal reached “sug-
gestive” or “signiﬁcant” evidence for linkage according
to the criteria of Lander and Kruglyak (1995). Our high-
est NPL and parametric LOD signals on each chromo-
some are shown in table 2. The highest signal across the
autosomes was observed on chromosome 10, with an
and a dominant maximumNPLp 3.35 HLODp
(mixing proportion ). This NPL corre-3.14 ap 100%
sponds to a genomewide P value of .035, based on sim-
ulations. Geneﬁnder results estimated a susceptibility lo-
cus at 110.4 cM (near D10S1686), with a 95% CI
around this location of 98.7–122.1 cM.
Other peaks with NPL 12 in this initial scan in-
clude chromosomes 1 ( ), 4 ( ),NPLp 2.45 NPLp 2.34
6 ( ), 7 ( ), 15 ( ),NPLp 2.37 NPLp 2.09 NPLp 2.15
and 21 ( ). The Genehunter locations andNPLp 2.04
parametric results are shown in table 2
Fine Mapping of Chromosome 10q
We chose to focus on our highest signal for immediate
follow-up. Twenty-three additional markers were chosen
between D10S537 and D10S1693 to attain a spacing of
∼1 Mb, and an additional affected aunt was available
for analysis at this point. The initial and follow-up link-
age plots for this region are shown in ﬁgure 2. Evidence
of linkage increased to , with a chromo-NPLp 4.27
somewide P value of .00002 at the peak location around
D10S1744. The 95% CI for the target region decreased
from 23.4 cM to 12.2 Mb (D10S1677–D10S1753 at
97.5–87.7Mb [UCSC genome browser]). Themaximum
HLOD under a dominant model also increased to 3.79
( ).ap 100%
Discussion
We have performed the ﬁrst genome scan for SZ sus-
ceptibility loci among an Ashkenazi Jewish sample of
multiplex pedigrees in hopes of reducing the underlying
heterogeneity among SZ linkage samples. Although our
strategy restricted recruitment to a relatively small num-
ber of families, we have potentially attained a more
homogeneous group for detection of linkage. For ex-
ample, parametric heterogeneity linkage analysis at
chromosome 10q implies that 100% of these families
show linkage to this locus, thus providing such a strong
signal among a small set of families. This chromosome
10 ﬁnding was the highest among our results, according
to both model-free and parametric analyses. When 23
new markers were added, evidence of linkage to this
region of chromosome 10 increased ( atNPLp 4.27
D10S1774; ), and a smaller 95% CI wasPp .00002
achieved for the gene location. In fact, analysis of the
new markers alone replicates evidence of linkage
( ; ), even in the absence of6NPLp 4.35 Pp 5.7# 10
the initial scan markers. To determine whether the in-
clusion of individuals with schizoaffective disorder
added genetic heterogeneity to our analyses, we subdi-
vided the families into two groups, those with at least
one relative with schizoaffective disorder ( 9) andNp
those without any relatives with schizoaffective disorder
( 0). Both groups of families had excess sharingNp 2
in this region and had a peak at D10S1774. Beyond
this chromosome 10q ﬁnding, ﬁve additional regions
(1p32.2, 4q34.3, 6p21.31, 7p15.2, and 21q21.2) appear
promising. We are currently pursuing ﬁne mapping of
these regions.
Our linkage signals do not overlap well with the
meta-analyses of previous SZ genome scans, consisting
mostly of outbred populations (Badner 2002; Lewis et
al. 2003). For example, other scans have shown linkage
to 10p at ∼45 cM from the p-terminus (Faraone et al.
1998; Schwab et al. 1998; Straub et al. 1998; Badner
and Gershon 2002). This is at least 50 cM from our
signal. However, a few smaller linkage studies have
shown some evidence of linkage to SZ and/or bipolar
disorder on 10q (Mowry et al. 2000; Cichon et al. 2001;
Ewald et al. 2002). These studies show a signal closer
to the p-terminus than ours, but the peak areas slightly
overlap. Given differences in methods, family numbers,
and family structures, these signals could potentially
represent the same underlying locus.
Also, our signal on chromosome 1 is on the opposite
end of the chromosome from the 1q ﬁnding of the SZ
meta-analysis. An association between the chromosome
1 hKCa3/KCNN3 gene and SZ has been observed
among Ashkenazi Jews (Dror et al. 1999); however, this
is located on the opposite arm of the chromosome from
our linkage peak. One interesting area is the overlap of
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Figure 1 Results of multipoint linkage analysis for the autosomes showing NPL scores (black) and HLOD for the dominant (red) and
recessive (blue) parametric models.
our 6p ﬁnding with previous linkage to an SZ locus in
this region (Straub et al. 1996; Kendler et al. 2000).
Several candidate genes have been identiﬁed in this
region, most notably dysbindin (Straub et al. 2002;
Schwab et al. 2003). Although our signal does not di-
rectly align with the location of this gene, the corre-
spondence is potentially important. Our second peak,
on chromosome 21, is ∼5–10Mb from the chromosome
21q11 linkage observed in bipolar families (Curtis 1999),
which may support an overlap in susceptibility to both
disorders. However, we did not see evidence for linkage
to the marker closest to the bipolar region in our fam-
ilies, and the importance of this peak in our data set
must be clariﬁed by further follow-up. Interestingly, our
Ashkenazi families did not produce a linkage signal on
chromosome 22, which contains the COMT gene that
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has been associated with SZ among Ashkenazim in Is-
rael (Shifman et al. 2002). Our sample may simply lack
the power to detect this gene through linkage analyses,
although our chromosome 10 ﬁnding implies that link-
age can be detected in this small, homogeneous set.
Our strong linkage ﬁnding on chromosome 10q is
encouraging for a small set of families and may attest
to the advantages of studying a relatively homogeneous
set of families to ﬁrst elucidate disease-related genes.
The discovery among Ashkenazim does not, however,
preclude the importance of genes found in this subgroup
among other, more outbred populations. In fact, genetic
variation associated with human disease among the
Ashkenazim is often found at detectable levels among
other populations and shown to have importance for
disease susceptibility in general (Schorge et al. 2001).
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Figure 2 Results of multipoint linkage analysis for the follow-up genotyping in the 10q region, showing NPL (black) and HLOD scores
for the dominant (red) and recessive (blue) parametric models. The NPL scores for three markers used in original 10-cM scan (marker names
in red) are indicated by the gray dashed line. The map location of polymorphisms was obtained from the November 2002 assembly of the
human genome.
Furthermore, identiﬁcation of any causal variation in
SZ, even for rare families, would be highly important
for our understanding of the disorder.
In summary, we observe a strong linkage signal for
SZ on chromosome 10q. Our evidence for linkage in-
creased upon follow-up and has resulted in a 12-Mb
region in which to perform additional linkage and as-
sociation analyses. Interestingly, several highly plausible
candidates lie within this region, including the serotonin
7 receptor, HTR7, and neuregulin 3, which is from the
same gene family as the NRG1 recently found to be
associated with SZ among Icelandic and Scottish pop-
ulations (Stefansson et al. 2002, 2003).We are currently
pursuing candidate gene studies as well as SNP-based
ﬁne mapping of this region.
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